Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical company focused on oncology, CNS, and metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a common antibiotic change how an experimental drug works? Results expected Sep 2026 (estimated)
- Radioactive tracer reveals the Body's journey of an experimental drug Results expected Sep 2026 (estimated)
- Lung cancer drug interaction study aims to uncover safe dosing Results expected Nov 2026 (estimated)
- New drug HS-20136-2 enters first human safety trial Results expected Dec 2026 (estimated)
- New lung cancer pill targets resistant mutations in early trial Results expected Dec 2026 (estimated)
-
New bladder gel could help patients avoid bladder removal surgery
Disease control Recruiting nowThis study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if th…
Phase 1/2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New lung cancer pill targets resistant mutations in early trial
Disease control Recruiting nowThis Phase 1 study tests a new daily pill called HS-10504 in 230 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR C797S mutation) and has stopped responding to earlier treatments. The main goal is to find the safest dose and check for side …
Phase 1 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for PNH patients: experimental drug HS-10542 enters human trials
Disease control Recruiting nowThis study tests a new drug called HS-10542 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The goal is to see if the drug can safely raise hemoglobin levels and reduce the need for blood transfusions. About 50 partic…
Phase 1/2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC